Manual práctico de Trombosis y Hemostasia de la SETH

— 2 1 9 — 5 . N e f r o l o g í a BIBLIOGRAFÍA 1. Documento Marco sobre Enfermedad Renal Crónica (ERC) den- tro de la Estrategia de Abordaje a la Cronicidad en el SNS. 2015. 2. Lutz J, Weinmann-Menke J. Bleeding in uremia. In: Management of Bleeding Patients; 2016 p. 151-7. DOI:10.1007/978-3-319- 30726-8_16. 3. Hedges SJ, Dehoney SB, Hooper JS, Amanzadeh J, Busti AJ. Evi- dence-based treatment recommendations for uremic bleeding. Nat Clin Pract Nephrol 2007;3(3):138-53. 4. Ma TK-W, Chow KM, Kwan BC-H, Leung CB, Szeto CC, Li PK-T. Manifestation of tranexamic acid toxicity in chronic kidney di- sease and kidney transplant patients: A report of four cases and review of literature. Nephrology 2017;22(4):316-21. 5. Lamba G, Kaur H, Adapa S, Shah D, Malhotra BK, Rafiyath SM, et al. Use of conjugated estrogens in life-threatening gastrointesti- nal bleeding in hemodialysis patients- A review. Clin ApplThromb 2013;19(3):334-7. 6. Cheung KL, Zakai NA, Folsom AR, Kurella Tamura M, Peralta CA, et al. Measures of Kidney Disease and the Risk of Venous Throm- boembolism in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study.Am J Kidney Dis 2017;70(2):182-90. 7. Rattazzi M, Villalta S, de Lucchi L, Sponchiado A, Galliazzo S, Faggin E, et al. Chronic kidney disease is associated with increa- sed risk of venous thromboembolism recurrence. Thromb Res 2017;160:32-7. 8. Dekkers IA, de Mutsert R, de Vries APJ, Rosendaal FR, Canne- gieter SC, Jukema JW, et al. Determinants of impaired renal and vascular function are associated with elevated levels of procoa- gulant factors in the general population. J Thromb Haemost 2018;16:519-28. 9. Yang K,Du C,Wang X,Li F,XuY,Wang S,et al.Uremic solute indoxyl sulfate-induced platelet hyperactivity contributes to CKD-asso- ciated thrombosis in mice. Blood 2017;11;129(19):2667-79. 10. Stępniewska J, Dołęgowska B C-HE.The activity of antioxidant en- zymes in blood platelets in different types of renal replacement the- rapy: a cross-sectional study. Int Urol Nephrol 2016;48(4):593-9. 11. Mörtberg J, Blombäck M, Wallén H, He S, Jacobson SH, Spaak J. Increased fibrin formation and impaired fibrinolytic capaci- ty in severe chronic kidney disease. Blood Coagul Fibrinolysis 2016;27(4):401-7. 12. Cho J, Jun KW, Kim MH, Hwang JK, Moon IS, Kim J Il. Coagulation profile in patients with chronic kidney disease before and after kidney transplantation: A retrospective cohort study. Clin Trans- plant 2017;31(9). DOI:10.1111/ctr.13051. 13. Kopel T, Kaufman JS, Hamburg N, Sampalis JS, Vita JA, Dember LM. Endothelium-dependent and -independent vascular func- tion in advanced chronic kidney disease. Clin J Am Soc Nephrol 2017;12(10):1588-94. 14. Helmke A, Vietinghoff S von. Extracellular vesicles as mediators of vascular inflammation in kidney disease. World J Nephrol 2016;5(2):125. 15. Dobry AS, Ko LN, St John J, Sloan JM, Nigwekar S, Kroshinsky D. Association Between Hypercoagulable Conditions and Calci- phylaxis in PatientsWith Renal Disease. JAMA Dermatology Dec 2018;154:182-7. 16. Ismail G, Mircescu G, Ditoiu AV,Tacu BD, Jurubita R, Harza M. Risk factors for predicting venous thromboembolism in patients with nephrotic syndrome: Focus on haemostasis-related parameters. Int Urol Nephrol 2014;46(4):787-92. 17. Salmela A, Ekstrand A, Joutsi-Korhonen L, Raisanen-Sokolowski A, Lassila. Activation of endothelium, coagulation and fibrinoly- sis is enhanced and associates with renal anti-neutrophil cyto- plasmic antibody-associated vasculitis. Nephrol Dial Transplant 2015;30(Suppl 1):53-9. 18. Berden AE, Nolan SL, Morris HL, Bertina RM, Erasmus DD, Ha- gen EC, et al. Anti-plasminogen antibodies compromise fibrinoly- sis and associate with renal histology in ANCA-associated vascu- litis. J Am Soc Nephrol 2010;21(12):2169-79. 19. Bilha SC, Burlacu A Siriopol D, Voroneanu L CA. Primary Pre- vention of Stroke in Chronic Kidney Disease Patients: A Scientific Update. Cerebrovasc Dis 2018;45(1-2):33-41. 20. Roldán V, Marín F, Manzano-Fernández S, Fernández H, Ga- llego P, Valdés M, et al. Does chronic kidney disease improve the predictive value of the CHADS2and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation? Thromb Haemost 2013;109(5):956-60. 21. Béland S, Vallin P, Désy O, Lévesque E, de Serres SA. Effects of alloantibodies to human leukocyte antigen on endothelial ex- pression and serum levels of thrombomodulin. J Thromb Hae- most 2017;15(5):1020-31. 22. Bijkerk R, Florijn BW, Khairoun M, Duijs JMGJ, Ocak G, de Vries APJ, et al. Acute Rejection After Kidney Transplantation Associa- tes With Circulating MicroRNAs and Vascular Injury. Transplant Direct 2017;3(7):e174. 23. Baas MC, Gerdes VEA, Ten Berge IJM, Heutinck KM, Florquin S, Meijers JCM, et al.Treatment with everolimus is associated with a procoagulant state.Thromb Res 2013;132(2):307-11. 24. Brahmbhatt A, Misra S.The Biology of Hemodialysis Vascular Ac- cess Failure. Semin Intervent Radiol 2016;33(1):15-20. 25. Burlacu A, Genovesi S, Goldsmith D, Rossignol P, Ortiz A, Kalra PA, et al. Bleeding in advanced CKD patients on antithrombo- tic medication – A critical appraisal. Pharmacol Res 2018;129: 535-43. 26. Franchi F, Rollini F, Angiolillo DJ. Defining the link between chronic kidney disease, high platelet reactivity, and clinical outcomes in clopidogrel-treated patients undergoing per- cutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(6)e002760. 27. Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, HohlfeldT, et al. Antiplatelet effects of aspirin in chronic kidney disease pa- tients. J Thromb Haemost 2016;14(2):375-80. 28. Bai Y, Chen H, Yang Y, Li L, Liu XY, Shi XB, et al. Safety of an- tithrombotic drugs in patients with atrial fibrillation and non- end-stage chronic kidney disease: Meta-analysis and systematic review.Thromb Res 2016;137:46-52. 29. Sharif-Askari S. Anticoagulation Therapy in Patients with Chronic Kidney Disease. Adv Exp Med Biol 2017;906:101-14. 30. Leizorovicz A, Siguret V, Mottier D. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein throm- bosis: The Innohep ® in Renal Insufficiency Study (IRIS). Thromb Res 2011;128(1):27-34.